These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28053505)

  • 21. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
    Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
    Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
    Pitisuttithum P; Velicer C; Luxembourg A
    Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
    Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
    Luxembourg A; Kjaer SK; Nygard M; Ellison MC; Group T; Marshall JB; Radley D; Saah A
    Contemp Clin Trials; 2017 Jan; 52():54-61. PubMed ID: 27777126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
    Guevara A; Cabello R; Woelber L; Moreira ED; Joura E; Reich O; Shields C; Ellison MC; Joshi A; Luxembourg A
    Vaccine; 2017 Sep; 35(37):5050-5057. PubMed ID: 28789851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
    Garland SM; Pitisuttithum P; Ngan HYS; Cho CH; Lee CY; Chen CA; Yang YC; Chu TY; Twu NF; Samakoses R; Takeuchi Y; Cheung TH; Kim SC; Huang LM; Kim BG; Kim YT; Kim KH; Song YS; Lalwani S; Kang JH; Sakamoto M; Ryu HS; Bhatla N; Yoshikawa H; Ellison MC; Han SR; Moeller E; Murata S; Ritter M; Sawata M; Shields C; Walia A; Perez G; Luxembourg A
    J Infect Dis; 2018 Jun; 218(1):95-108. PubMed ID: 29767739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
    Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
    Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
    Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
    Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study.
    Rahman S; Pierce Campbell CM; Rollison DE; Wang W; Waterboer T; Michel A; Pawlita M; Villa LL; Lazcano Ponce E; Borenstein AR; Giuliano AR
    PLoS One; 2016; 11(11):e0167173. PubMed ID: 27902759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of Human Papillomavirus Vaccines: An Updated Review.
    Phillips A; Patel C; Pillsbury A; Brotherton J; Macartney K
    Drug Saf; 2018 Apr; 41(4):329-346. PubMed ID: 29280070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of the 9-valent HPV vaccine in men.
    Castellsagué X; Giuliano AR; Goldstone S; Guevara A; Mogensen O; Palefsky JM; Group T; Shields C; Liu K; Maansson R; Luxembourg A; Kaplan SS
    Vaccine; 2015 Nov; 33(48):6892-901. PubMed ID: 26144901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia.
    Wnukowski-Mtonga P; Jayasinghe S; Chiu C; Macartney K; Brotherton J; Donovan B; Hall M; Smith DW; Peterson K; Campbell-Lloyd S; Selvey C; Giles M; Kaldor J; Marshall H;
    Commun Dis Intell (2018); 2020 Apr; 44():. PubMed ID: 32299331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S; Gasparini R; Panatto D; Demarteau N
    Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.
    Chesson HW; Laprise JF; Brisson M; Markowitz LE
    J Infect Dis; 2016 Jun; 213(11):1694-700. PubMed ID: 26908738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HPV vaccine cross-protection: Highlights on additional clinical benefit.
    De Vincenzo R; Ricci C; Conte C; Scambia G
    Gynecol Oncol; 2013 Sep; 130(3):642-51. PubMed ID: 23747835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men.
    Giuliano AR; Wilkin T; Bautista OM; Cheon K; Connor L; Dubey S; ; Luxembourg A; Rawat S; Shaw A; Velicer C; Vendetti N; Tu Y
    Contemp Clin Trials; 2022 Apr; 115():106592. PubMed ID: 34678491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.